Program
Ranolazine
Also written as “Test formulation (Ranolazine extended-release tablets)”, “Reference formulation (Ranolazine extended-release tablets)” and “Ranolazine 500 mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Angina Pectoris · Atrial Fibrillation · Coronary Artery Disease · Cardiovascular Diseases, led by 7 companies.
Drug pageRanolazine: every studyMany companies study it; this page follows only the 25 they lead. All 85 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 180 open or running | phase 4since Mar 24, 2008 | Sep 8, 2004 | none ahead |
| Menarini Groupits history only | 20 open or running | phase 2since Feb 10, 2012 | Feb 10, 2012 | none ahead |
| Amit Malhotra, MDits history only | 10 open or running | phase 4since Jan 26, 2017 | Jan 26, 2017 | none ahead |
| Haisco Pharmaceutical Groupits history only | 10 open or running | phase 1since Jun 27, 2025 | Jun 27, 2025 | none ahead |
| Novartis | 10 open or running | phase 2since Mar 21, 2012 | Mar 21, 2012 | none ahead |
| OBS Pakistanits history only | 10 open or running | phase 4since Mar 15, 2018 | Mar 15, 2018 | none ahead |
| TSH Biopharmits history only | 10 open or running | no phasesince Jan 7, 2018 | Jan 7, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 21, 2012First study: phase 2 study in Cardiovascular DiseasesFirst studyNCT01562041 · 14 enrolled · United States
TargetBeta
“Sodium channel protein type V alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Quinidinerule | Otsuka | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
The one study Novartis leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01562041Cardiovascular Diseases · United States | 2 | Terminated | Jan 2, 2014 | 14 |
How it is read
Names in the registry
- “Ranolazine”, 24 entries
- “Test formulation (Ranolazine extended-release tablets)”, 1 entry
- “Reference formulation (Ranolazine extended-release tablets)”, 1 entry
- “Ranolazine 500 mg”, 1 entry
- “Ranolazine plus Metoprolol Combination”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 7 studies
- Angina Pectoris, 5 studies
- Atrial Fibrillation, 3 studies
- Coronary Artery Disease, 2 studies
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.